丙戊酸钠缓释片联合盐酸齐拉西酮治疗双相情感障碍躁狂发作的临床疗效

Clinical efficacy of compound sodium valproate and valproic acid sustained-release tablets combined with ziprasidone hydrochloride in the treatment of manic episodes of bipolar disorder

目的分析丙戊酸钠缓释片联合盐酸齐拉西酮治疗双相情感障碍躁狂发作的临床疗效。方法106例双相情感障碍躁狂发作患者作为研究对象,按照入院顺序奇偶性分为观察组和对照组,每组53例。两组患者均给予丙戊酸钠缓释片进行治疗,观察组患者在此基础上同时给予盐酸齐拉西酮进行治疗。比较两组患者临床疗效、治疗前后贝克-拉范森躁狂量表(BRMS)评分、认知功能连线测试(TMT)评分及副反应量表(TESS)评分。结果观察组患者的临床治疗总有效率为90.57%,高于对照组的73.58%,差异有统计学意义(P<0.05)。观察组患者治疗1、3、6周后BRMS评分分别为(26.92±6.16)、(18.38±5.18)、(9.68±4.26)分,均低于治疗前的(31.38±7.88)分,差异有统计学意义(P<0.05);对照组患者治疗1、3、6周后BRMS评分分别为(27.55±6.85)、(23.57±5.08)、(20.04±5.09)分,均低于治疗前的(31.46±8.59)分,差异有统计学意义(P<0.05);两组患者治疗1周后的BRMS评分比较差异无统计学意义(P>0.05);治疗3、6周后,观察组患者的BRMS评分均低于对照组,差异有统计学意义(P<0.05)。观察组患者的TMT中字母、数字评分分别为(83.07±7.13)、(58.24±4.97)分,均低于对照组的(87.87±8.27)、(63.58±6.38)分,差异有统计学意义(P<0.05);两组患者的TESS评分比较差异无统计学意义(P>0.05)。结论丙戊酸钠缓释片联合盐酸齐拉西酮治疗双相情感障碍躁狂发作疗效显著,能够显著改善患者的躁狂症状、提升认知功能,且不会增加患者的脂代谢异常风险。

Objective To analyze the clinical efficacy of compound sodium valproate and valproic acid sustained-release tablets combined with ziprasidone hydrochloride in the treatment of manic episodes of bipolar disorder.Methods A total of 106 patients with manic episodes of bipolar disorder were studied and divided into observation group and control group according to the parity of admission order,with 53 cases in each group.Both groups were treated with compound sodium valproate and valproic acid sustained-release tablets,and the observation group was also treated with ziprasidone hydrochloride on this basis.Both groups were compared in terms of clinical efficacy,Bech-Rafaelsdn mania rating scale(BRMS)score,trail-making test(TMT)score and treatment emergent symptom scale(TESS)score.Results The total effective rate of clinical treatment in the observation group was 90.57%,which was higher than 73.58%in the control group,and the difference was statistically significant(P<0.05).After 1,3,and 6 weeks of treatment,BRMS scores of the observation group were(26.92±6.16),(18.38±5.18),(9.68±4.26)points,respectively,which were lower than(31.38±7.88)points before treatment,and the difference was statistically significant(P<0.05);BRMS scores of the control group were(27.55±6.85),(23.57±5.08),(20.04±5.09)points,respectively,which were lower than(31.46±8.59)points before treatment,and the difference was statistically significant(P<0.05).There was no statistically significant difference in BRMS scores between the two groups after 1 week of treatment(P>0.05).After 3 and 6 weeks of treatment,BRMS scores of the observation group were lower than those of the control group,and the difference was statistically significant(P<0.05).The letter and number scores in the TMT of patients in the observation group were(83.07±7.13)and(58.24±4.97)points,which were lower than(87.87±8.27)and(63.58±6.38)points in the control group,and the differences were statistically significant(P<0.05),but there was no statistically significant difference in between the the two groups of TESS scores(P>0.05).Conclusion Combination of compound sodium valproate and valproic acid sustained-release tablets and ziprasidone hydrochloride has significant effect on the treatment of manic episodes of bipolar disorder,and it can significantly improve the patient’s manic symptoms,enhance the patient’s cognitive function without increasing the risk of abnormal lipid metabolism.